We are a clinical-stage biopharmaceutical company in China focusing on the discovery and development of differentiated antibody drugs. We aspire to become a globally integrated biopharmaceutical company. Our mission is to translate scientific breakthroughs in immunology and biology into novel antibody therapies that target a wide range of autoimmune diseases and oncology, addressing significant unmet medical needs and market potential in China and globally. We will leverage this opportunity to continuously provide innovative and affordable treatment solutions for patients.
Building on our strong foundation in biomedical research, we have developed in-houseproprietary antibody discovery and development technology platforms, including the ADCC-enhanced antibody platform, the multispecific antibody platform, the half-life extended antibody platform, the antibody discovery and optimization platform and the process development and industrialization platform. Our ADCC-enhanced antibody platform is one of the leading platforms in the world to enhance NK-cell function through antibody glycosylation modification. It also meets GMP manufacturing standards in China and has undergone clinical validation. Our multi-specific antibody platform enables us to develop antibodies simultaneously binding to different targets to achieve synergistic therapeutic functions. Our half-life extended antibody platform integrates advanced antibody engineering technologies to optimize the pharmacokinetic properties of antibodies, enabling longer dosing intervals and thereby enhancing patient compliance in treatment. Our antibody platforms encompass the entire process from antibody discovery to development, enabling us to efficiently design, evaluate, select and develop the most promising drug candidates.
Leveraging our proprietary antibody platforms, we have developed a differentiated pipeline comprising several clinical-stage and preclinical drug candidates. Our Core Product, known as MIL62, is a novel 3rd-generation anti-CD20 antibody that has been granted “Breakthrough Therapy Designation” by the National Medical Products Administration (NMPA) in China for the treatment of primary membranous nephropathy (PMN) as the first kidney drug produced by the Chinese pharma. Its New Drug Applications (NDAs) for both the PMN and Neuromyelitis Optica Spectrum Disorders ( NMOSD ) indications have been accepted by NMPA and under "the Priority Review" program. MIL62 is expected to become the first approved targeted therapy for both PMN and NMOSD in China. MBS303/MSC303 is a novel CD20/CD3 T-cell engager (TCE) with the potential to benefit a wide range of patients with immune-mediated glomerulonephritis and hematological malignancies. MBS314 is a novel GPRC5D/BCMA/CD3 TCE providing a potentially superior solution for patients with multiple myeloma. MIL116 is a novel anti-APRIL antibody that offers a more effective and convenient potential treatment option for patients with IgA nephropathy.
Our industry leading antibody R&D, manufacturing and commercialization capabilities have been recognized and validated through various strategic collaborations with leading pharmaceutical companies in China and globally. We have established partnerships with companies including Climb Bio (NYSE: CLYM), Betta (300558.SZ), Kawin (688687.SH) and Kyinno Bio at various stages. We anticipate that these partnerships will create substantial synergy with our internal R&D efforts and help us maximize the clinical and commercial value of our products.
